Profluent debuts AI model for CRISPR design, hoping to expand gene editing's potential

Andrew Dunn

Senior Biopharma Correspondent

Bay Area biotech Profluent has taken another step in using AI to design new CRISPR gene editing systems, CEO Ali Madani exclusively told Endpoints News …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Profluent debuts AI model for CRISPR design, hoping to expand gene editing's potential

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

J&J's new cancer combo beats AstraZeneca's Tagrisso on survival in lung trial

FDA sets an efficacy threshold for future weight loss drugs

Sanofi partners with Alloy Therapeutics to make new CNS drug

Calico, Denali's ALS drugs miss primary objectives in basket study

Vertex signs in vivo gene editing delivery pact for sickle cell and thalassemia as it looks beyond Casgevy

Metsera’s long-acting GLP-1 looks competitive in Phase 2 obesity study

Proflu­ent de­buts AI mod­el for CRISPR de­sign, hop­ing to ex­pand gene edit­ing's po­ten­tial

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

FDA sets an ef­fi­ca­cy thresh­old for fu­ture weight loss drugs

Sanofi part­ners with Al­loy Ther­a­peu­tics to make new CNS drug

Cal­i­co, De­nal­i's ALS drugs miss pri­ma­ry ob­jec­tives in bas­ket study

Ver­tex signs in vi­vo gene edit­ing de­liv­ery pact for sick­le cell and tha­lassemia as it looks be­yond Cas­gevy

Met­sera’s long-act­ing GLP-1 looks com­pet­i­tive in Phase 2 obe­si­ty study

Profluent debuts AI model for CRISPR design, hoping to expand gene editing's potential

J&J's new cancer combo beats AstraZeneca's Tagrisso on survival in lung trial

FDA sets an efficacy threshold for future weight loss drugs

Sanofi partners with Alloy Therapeutics to make new CNS drug

Calico, Denali's ALS drugs miss primary objectives in basket study

Vertex signs in vivo gene editing delivery pact for sickle cell and thalassemia as it looks beyond Casgevy

Metsera’s long-acting GLP-1 looks competitive in Phase 2 obesity study